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Background: To systematically assess the current clinical evidence of acupuncture for hypertension.
Search strategy: The PubMed, EMBASE, Chinese Biomedical Literature Database (CBM), Chinese National Knowl-
edge Infrastructure (CNKI), Chinese Scientiﬁc Journal Database (VIP), andWan-fang Data in the Cochrane Library
were searched until January, 2013. All the randomized controlled trials (RCTs) based on acupuncture compared
withwesternmedicine, sham acupuncture or lifestyle intervention in patients with hypertensionwere included.
RCTs were included as well as combined acupuncture with westernmedicine comparedwith westernmedicine.
In addition, RCTs based on acupuncture compared with sham acupuncture combined with western medicine
in patients with essential hypertension were included. No language restriction was used. Review Manager 5.1
software was used for data analysis. Study selection, data extraction, quality assessment, and data analyses
were conducted according to the Cochrane standards.
Results: 35 randomized trials (involving 2539 patients) were included. The methodological quality of the included
trials was evaluated as generally low. Two trials reported the effect of acupuncture compared with sham acupunc-
ture in combinations of western medicine. Acupuncture signiﬁcantly reduced SBP (−7.47 mm Hg, 95% CI— 10.43
to−4.5, P b 0.00001) andDBP (−4.22 mm Hg, 95%CI—6.26 to−2.18, P b 0.0001) andnoheterogeneity between
studieswasdetected.However, other studies had substantial heterogeneity due to the quality of themwas poor, and
their sample sizes were not satisfactory as an equivalence study. Five trials described the adverse effects.
Conclusions:While there are some evidences that suggest potential effectiveness of acupuncture for hypertension,
the results were limited by the methodological ﬂaws of the studies. Therefore, further thorough investigation,
large-scale, proper study designed, randomized trials of acupuncture for hypertension will be required to justify
the effects reported here.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Hypertension is a well-recognized risk factor for cardiovascular dis-
ease and stroke, which are the most frequent cause of deaths all over
the world [1,2]. It has been estimated that 29% of the world's adult
population, or ≈1.56 billion people, will have hypertension by the
year of 2025 [3]. Essential hypertension (EH), a complex disease,
which accounts for 95% of hypertensive cases, is an increasingly serious
worldwide public-health challenge and is generally considered as a par-
adigmaticmulti-factorial disease that is determined by a combination of
genetic factors, environmental stimuli and their interaction [4,5]. The
prevention and management of hypertension are major public health, Guang'anmen Hospital, China
cheng District, Beijing 100053,
land Ltd. Open access under CC BY-Nchallenges. Evidence from randomized control trials (RCTs) has showed
that a small reduction in blood pressure (BP) may result in a large re-
duction in the risk of stroke andmyocardial infarction [6,7]. The antihy-
pertensive treatment has made great progress in modern medicine.
The therapeutic drugs include six classes of antihypertensive agents
and ﬁxed compound preparation [8–10]. However, there is concern
that the beneﬁts demonstrated in RCTs of antihypertensive medication
are not implemented in everyday clinical practice and that the long-
term use of western medicine will produce some side effects, even pro-
duce resistance and affect therapeutic efﬁcacy, only 53% of patients
treated for hypertension had blood pressure actually controlled to
≤140/90 mm Hg [11,12]. Therefore, seeking for a new effective decom-
pression method is an important subject of hypertension treatment.
Complementary and alternative medicine (CAM) is recognized and
accepted in Europe and America that have developed a high degree of
modern medicine, as an important complement to the western main-
stream medicine system [13,14]. Recent researches showed that CAM
could be regularly recommended for lowering elevated blood pressure
(BP) [15–17]. Traditional ChineseMedicine (TCM) is amain component
of CAM, including herbal medicine, acupuncture, moxibustion, and cup-
ping, Taichi and Qigong. Acupuncture has been a component of theC-ND license.
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ticed in the United States [18]. Acupuncture is based on the TCM concept
that there are channels (or “meridians”) of energy ﬂow (“qi”) within
the body that help maintain the health of the individual and that dis-
ease and pain result from imbalances of qi [19]. Acupuncture as a
nonpharmacological intervention has been used to treat a wide variety
of condition to regulate cardiovascular diseases, and acupuncture ther-
apy is used on patients withmild or borderline hypertension whowant
to avoid treatment cost, adverse effects, and complications [20]. Possi-
ble mechanisms by which acupuncture reduces blood pressure in
hypertensive patients include decreases in plasma renin, aldosterone
and angiotensin II activity [21,22], increased excretion of sodium and
changes in plasma norepinephrine, serotonin and endorphin levels
[23,24]. Meanwhile, there have been a large number of clinical trials
of acupuncture on hypertension and RCTs [25,26]. In addition, several
reviews claimed that acupuncture has therapeutic effects on blood
pressure in patients with hypertension [27,28]. These reviews are, how-
ever, non-systematic and are therefore open to bias. The aim of this
systematic review is to assess randomized clinical trials (RCTs) rigor-
ously testing the effectiveness of acupuncture in human patients with
hypertension.
2. Materials and methods
The supporting PRISMAchecklist is available as supporting information; see Checklist S1.
2.1. Database and search strategies
Literature searches were conducted in the Cochrane Central Register of Controlled
Trials (CENTRAL) in the Cochrane Library (January, 2013), the PubMed, EMBASE, Chinese
Biomedical Literature Database (CBM), Chinese National Knowledge Infrastructure (CNKI),
Chinese Scientiﬁc Journal Database (VIP), Wan-fang Data. Databases in Chinese were
searched to retrieve the maximum possible number of trials of acupuncture for essential
hypertension because acupuncture is mainly used and researched in China. All of those
searches ended on January, 2013. Ongoing registered clinical trials were searched in
the website of international clinical trial registry by U.S. National Institutes of Health
(http://clinicaltrials.gov/). The following search terms were used individually or
combined: ‘hypertension’, ‘blood pressure’, ‘essential hypertension’, ‘acupuncture’,
‘electroacupuncture’ (EA), ‘clinical trial’, and ‘randomized controlled trial’. The bibli-
ographies of included studies were searched for additional references.
2.2. Inclusion criteria
All the parallel randomized controlled trials (RCTs) of all the prescriptions based on
“acupuncture” compared with westernmedicine, sham acupuncture or lifestyle interven-
tion in patients with hypertension were included. RCTs were included as well, combined
“acupuncture” with western medicine compared with western medicine. In addition,
RCTs based on acupuncture compared with sham acupuncture combined with western
medicine in patients with essential hypertension were included. Studies were excluded
if they were nonrandomized studies and/or involving other forms of acupuncture such
as transcutaneous electrical nerve stimulation, laser acupuncture. There were no restric-
tions on population characteristics, language and publication type. The main outcome
measurewas blood pressure. Duplicated publications reporting the same groups of partic-
ipants were excluded.
2.3. Data extraction and quality assessment
Two reviewers (W. Liu, X. J. Xiong) extracted data and evaluated data's quality and
content independently. We conducted data extraction using a standardized procedure.
Initially, abstracts were screened to exclude obviously ineligible reports, and then all
remaining articles were reviewed. We classiﬁed trials and abstracts according to patient
characteristics, study design, and therapy duration. Reviewing study design included the
following criteria: methods of sequence generation, allocation concealment, complete
description of thosewhowere blinded, and use of intention-to-treat analysis andwhether
the trialwas stopped prior to the plannedduration, all methodological features in addition
capable of impacting effect sizes. The outcomemeasures included BP and adverse events.
The data was entered into an electronic database by the two reviewers separately,
avoiding duplicate entries; in the case where the two entries did not match, an inspection
will be conducted, and a third person may be involved for veriﬁcation. In order to obtain
full information regarding conference abstracts, we had contacted the study authors by
email and/or telephone communication. Disagreement was resolved by discussion and
reached consensus through a third party (J. Wang).
The methodological quality of trials was assessed independently using criteria from
the Cochrane Handbook for Systematic Review of Interventions, Version 5.1.0 (W. Liu,
X. J. Xiong) [29]. The items included random sequence generation (selection bias),allocation concealment (selection bias), blinding of participants and personnel (perfor-
mance bias), blinding of outcome assessment (detection bias), incomplete outcome data
(attrition bias), selective reporting (reporting bias), and other biases. The quality of all the
included trials was categorized to low/unclear/high risk of bias (“Yes” for a low of bias,
“No” for a high risk of bias, “Unclear” otherwise). Then trials were categorized into three
levels: low risk of bias (all the items were in low risk of bias), high risk of bias (at least
one item was in high risk of bias), unclear risk of bias (at least one item was in unclear).
2.4. Risk of bias across studies
Funnel plots were generated to visualize the possible publication bias.
2.5. Data synthesis
We used Revman 5.1 software provided by the Cochrane Collaboration for data anal-
yses. Studies were stratiﬁed by the type of comparison. Continuous outcome will be
presented as mean difference (MD) and its 95% CI. Heterogeneity was recognized signiﬁ-
cant when I2 ≥ 50%. Fixed effects model was used if there is no signiﬁcant heterogeneity
of the data; random effects model was used if signiﬁcant heterogeneity existed (50% b
I2 b 85%). Publication bias was explored using a funnel plot.
3. Results
3.1. Description of included trials
A ﬂow chart depicted the search process and study selection (as
shown in Fig. 1). After primary searches from the databases, 1081 arti-
cles were screened. After reading the titles and abstracts, 976 articles
of them were excluded. Full texts of 35 articles [30–64] were retrieved,
and 70 articles were excluded with reasons listed as the following:
participants did not meet the inclusive criteria (n = 34), duplication
(n = 5), no control group (n = 10), Patients complicated with other
diseases (n = 10) and no data for extraction (n = 11). In the end, 35
RCTs were included, and all trials had been conducted in four different
countries, most of the RCTs were conducted in China and published
in Chinese (31 trials), a German journal [61], and English journals
[60,62,63]. The characteristics of included trials were listed in Table 1.
2539 patients with essential hypertension were included, with the
average number of 72 per trial, ranging from 14 to 192. There was a
wide variation in the age of subjects (18–78 years). 24 trials speciﬁed
10 diagnostic criteria of hypertension, 11 trials [34,35,38,41,46–48,
50,52,55,64] used 1999 WHO–ISH guidelines for the management of
hypertension (1999 WHO–ISH GMH), 3 trials [30,40,56] used 1998
WHO–ISH guidelines for the management of hypertension (1998
WHO–ISH GMH), 3 trials [39,42,49] used Chinese Guidelines for the
Management of Hypertension—2005 (CGMH—2005), one trials [37]
used China Guidelines on Prevention and Management of High
Blood Pressure—2006 (CGPMHBP—2006), 3 trials [43,44,51] used
2000 WHO–ISH guidelines for the management of hypertension
(2000 WHO–ISH GMH), one trial [58] used the National Forum on
Epidemiology of Cardiovascular Diseases in 1979, 2 trials [31,54] used
1978 WHO–ISH guidelines for the management of hypertension
(1978 WHO–ISH GMH), 2 trials [53,60] used the Seventh Report of
the Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure (JNC 7), one trial used the pre-
vention and control of hypertension guidelines of China 2004, one
trial [63] used European Society of Hypertension–European Society
of Cardiology Guidelines 2003, and 7 trials [32,33,36,45,57,61,62] only
demonstrated patients with essential hypertension.
Interventions included acupuncture or electro-acupuncture alone,
or combined with western medicine. Acupuncture was the sole treat-
ment in 25 trials, whereas in 10 trials, acupuncture was used as an
adjunct treatment for medication. The controls included western medi-
cine compared alone, sham acupuncture or combined with western
medicine, and lifestyle intervention. As for control, sham acupuncture
was adopted for control in 3 trials [61,62], 2 trials [57,63] used sham
acupuncture plus western medicine, whereas 29 [30–56,58,59] and
one trial [64] used lifestyle intervention. Participants received 10 to
30 min per session acupuncture treatments for mean 32 days (ranged
Fig. 1. PRISMA 2009 Flow diagram.
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(LI4), Tai Chong (LR3), Feng Chi (GB20), Qu Chi (LI11), and Bai Hui
(GV20), followed by, Feng Long (ST40) and Nei Guan (PC6). All of the
24 trials used the BP as the outcome measure, and 5 trials described
the adverse effect [54,57,60–62].
3.2. Methodological quality of included trials
The methodological quality of most included trials was generally
“poor” according to the predeﬁned quality assessment criteria
(Table 2). The randomized allocation of participants was mentioned in
all trials; however, only 8 trials stated the methods for sequence gener-
ation including random number table [30,36,37,50,57,59,62] and draw-
ing [34]. However, insufﬁcient information was provided to judge
whether or not it was conducted properly. Allocation concealment
was only mentioned in 4 RCTs [57,60,62,63]. Double-blind was not
mentioned in all trials. However, as the testing acupuncture and con-
trolled drug were in different forms, neither the participants nor the
investigators were likely to be blinded. Only one trial reported drop-out or withdraw [59]. However, the trial did not intend to analyze the
cause, and no trials used intention-to-treat analysis. None of the trials
had a pre-trial estimation of sample size. Five trails reported information
on follow-up [32,53,59,61,62]. Selective reporting was generally unclear
in the RCTs due to the inaccessibility of the trail protocol.
3.3. Effect of the interventions
35 RCTswere included in the group of studies of patientswith essen-
tial hypertension ([30–64]). The effect estimates of acupuncture were
shown in the Figs. 2–3.
3.3.1. Acupuncture versus western medicine
A total of 19 trials [30,31,33,34,37,41,42,44–52,54,55,59] reported
the effect of acupuncture compared with western medicine on hyper-
tension. A change in blood pressure was reported in 11 trials [37,41,
42,44,45,47,48,50,52,54,59] of the included RCTs.
Only 4 independent trials did show better effect: Yang [37] demon-
strated that electro-acupuncture on Qu Chi (LI11) and Tai Chong (LR3)
Table 1
Characteristics and methodological quality of included studies.
Study ID Sample (M/F) Age (yrs) Diagnosis standard Intervention Control Course (day) Outcome
measure
Feng andWu [30] 60
T:18/12; C:14/16
T:47.35 ± 11.59
C:48.35 ± 10.64
1998 WHO–ISH GMH Acupuncture Captopril tablets
(25 mg tid)
30 (7 days/week;
20 min per day)
BP
Li and Niu [31] 59
T:15/13; C:17/14
T:61.4 ± 9.2
C:61.7 ± 9.6
1978 WHO–ISH GMH Acupuncture Nimodipine (40 mg tid) 10 (30 min per day,
5 days/course)
BP
Luo [32] 68
T:25/13; C:21/9
T:61.2
C:63.2
Hypertension diagnostic
criteria (unclear)
Acupuncture plus
western medicine
Western medicine 90 (15 days/course) BP
Liu [33] 50
M/F:18:32;
T:24; C:26
18 to 70
(T/Cnot reported)
Hypertension diagnostic
criteria (unclear)
Acupuncture Captopril tablets 30 (once a day,
10 days/course)
BP
Yang and
Zhou [34]
60
M/F:35:25; T1:20
T2:20 C:20
35 to 75
(T/Cnot reported)
1999 WHO–ISH GMH Acupuncture Hydrochlorothiazide
(12.5–25 mg bid)
21 (once a day,
7 days/course)
BP
Liu [35] 86
T:25/23; C:22/16
T:63.2
C:61.5
1999 WHO–ISH GMH Acupuncture plus
western medicine
Captopril tablets
(12.5 mg bid or tid)
90 (once a day,
15 days/course)
BP
Zhang [36] 80
T:29/16; C:24/11
T:53.62 ± 9. 83
C:52.16 ± 10.04
Hypertension diagnostic
criteria (unclear)
Acupuncture plus
western medicine
Benzene sulfonic acid
amlodipine piece
(2.5 mg qd)
28 (20 min per day,
28 days/course)
BP
Yang [37] 98
T:17/13; C:20/10
T:40.4 ± 5.2
C:41.7 ± 4.2
China Guidelines on
Prevention andManagement
of High Blood Pressure—
2006 (CGPMHBP—2006)
Electroacupuncture Captopril tablets
(12.5 mg tid)
14 (30 min once a day) BP
Wang and
Cheng [38]
59
34/25
25 to 60
(T/Cnot reported)
1999 WHO–ISH GMH Electroacupuncture
pluswesternmedicine
Benazepril hydrochloride
tablets (10 mg qd)
56 (30 min once a day,
56 days/course)
BP
Jia et al. [39] 92
T:32/14; C:30/16
T:46.4 ± 5.7
C:44.7 ± 6.8
Chinese Guidelines for
the Management of
Hypertension—2005
(CGMH—2005)
Acupuncture plus
western medicine
Left-hand amlodipine
(5 mg qd)
30 (30 min per day,
28 days/course)
BP
Liu et al. [40] 106
T:30/23; C:28/25
T:46.4 ± 5.2
C:45.2 ± 6.3
1998 WHO–ISH GMH Acupuncture plus
western medicine
Captopril tablets
(12.5 mg tid)
30 (20 min per day) BP
Liao et al. [41] 90
T:31/28; C:17/14
T:56.5 ± 7.9
C:55.6 ± 8.6
1999 WHO–ISH GMH Acupuncture Captopril tablets
(12.5 mg tid) and
Aspirin enteric-coated
tablets (75 mg qd)
14 (30 min every
time; twice a day,
7 days/course)
BP
Ma et al. [42] 80
T:25/15; C:22/18
T:66.39 ± 5.4
C:64.58 ± 7.1
Chinese Guidelines for
the Management of
Hypertension—2005
(CGMH—2005)
Electroacupuncture Nicardipine piece
(20 mg tid)
15 (10 min once a day,
15 days/course)
BP
Hu et al. [43] 60
T:20/10; C:22/8
T:77.8 ± 4.2
C:77.1 ± 3.4
2000 WHO–ISH guidelines
for the management
of hypertension
(2000 WHO–ISH GMH)
Acupuncture plus
western medicine
Amlodipine (5 mg qd) 20 (30 min once a day,
10 days/course)
BP
Chen et al. [44] 70
T:19/16; C:19/16
T:63.57 ± 8.08
C:65.20 ± 8.86
2000 WHO–ISH GMH Acupuncture Nifedipine (10–20 mg tid) 14(15–30 min once a
day, 14 days/course)
BP
Guo et al. [45] 60
T:16/14; C:17/13
T:32 to 64
C:32 to 65
Hypertension diagnostic
criteria (unclear)
Acupuncture Enalapril maleate
(10 mg qd)
30 (30 min once a day,
28 days/course)
BP
Huang et al. [46] 60
T:18/12; C:20/10
T:54.75 ± 7.12
C:51.72 ± 10.38
1999 WHO–ISH GMH Acupuncture Metoprolol (100 mg qd) 14 (30 minonce a day) BP
Wang et al. [47] 60
T:20/10; C:21/9
T:54.75 ± 7.1
C:67.8 ± 12.0
1999 WHO–ISH GMH Acupuncture Metoprolol (100 mg qd) 28 (30 min once a day,
14 days/course)
BP
Guo [48] 80
T:22/18; C:23/17
T:43.84 ± 8.3
C:44.20 ± 8.4
1999 WHO–ISH GMH Acupuncture Enalapril maleate
(10 mg qd)
30 (30 min once a day,
30 days/course)
BP
Cheng [49] 84
T:27/15; C:24/18
30 to 65
(T/Cnot reported)
Chinese Guidelines for
the Management of
Hypertension—2005
(CGMH—2005)
Acupuncture Levamlodipine besylate
tablets (2.5 mg qd)
20 (30 min every time,
the next day at a time,
10 times/course)
BP
Huang et al. [50] 60
T:14/16; C:13/17
T:56.51 ± 6.28
C:58.12 ± 6.15
1999 WHO–ISH GMH Acupuncture Captopril tablets
(25 mg tid)
28 (30 min every time) BP
Zhang et al. [51] 60
T:22/8; C:20/10
T:56.5
C:55.5
2000 WHO–ISH GMH Acupuncture Compound reserpine
tablets (1 tablet tid)
15 (30 minonce a day) BP
Ye et al. [52] 100
T:28/22; C:26/24
T:42 to 64
C:41 to 64
1999 WHO–ISH GMH Acupuncture Metoprolol sustained
release tablet (12.5 mg bid)
14 (30 minonce a day) BP
Shen et al. [53] 50
T:15/10; C:16/9
T:57.32 ± 8.2
C:58.21 ± 7.3
Seventh Report of the Joint
National Committee on
Prevention, Detection,
Evaluation, and Treatment of
High Blood Pressure (JNC 7)
Acupuncture plus
western medicine
Extended release
Nifedipine tablets
(20 mg bid)
25 (30 min once a day,
10 days/course)
BP
Dan [54] 52
T:19/7; C:18/8
T:57.8 ± 10.9
C:58.4 ± 11.6
1978 WHO–ISH GMH Acupuncture Nifedipine (10 mg tid) 21 (20–30 min once a
day, 5 days/week)
BP; adverse
effect
Wu et al. [55] 60
T1:7/13;
T2;6/14 C:11/9
T1:55.9 ± 8.1
T2:55.6 ± 6.0
C:55.00 ± 6.4
1999 WHO–ISH GMH Acupuncture Captopril tablets
(25 mg tid)
5 (30 min once a day,
5 days/course)
BP
Zhang et al. [56] 75
T:28/17; C:19/11
T:63.60 ± 8.20
C:65.20 ± 8.00
1998 WHO–ISH GMH Acupuncture plus
western medicine
Nifedipine (10 mg tid) 20 (30 min once a day,
20 days/course)
BP
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Table 2
Quality assessment of included randomized controlled trials.
Included trials Random sequence
generation
Allocation
concealment
Blinding of participants
and personnel
Blinding of outcome
assessment
Incomplete
outcome data
Selective
reporting
Other sources
of bias
Risk of
bias
Feng [30] Table of random number Unclear Unclear Unclear Yes No Unclear Unclear
Li [31] Unclear Unclear Unclear Unclear Yes No Unclear High
Luo [32] Unclear Unclear Unclear Unclear Yes No Unclear High
Liu [33] Unclear Unclear Unclear Unclear Yes No Unclear High
Yang [34] Drawing Unclear Unclear Unclear Yes No Unclear Unclear
Liu [35] Unclear Unclear Unclear Unclear Yes No Unclear High
Zhang [36] Table of random number Unclear Unclear Unclear Yes No Unclear Unclear
Yang [37] Table of random number Unclear Unclear Unclear No No Unclear Unclear
Wang [38] Unclear Unclear Unclear Unclear No No Unclear High
Jia et al. [39] Unclear Unclear Unclear Unclear No No Unclear High
Liu et al. [40] Unclear Unclear Unclear Unclear No No Unclear High
Liao et al. [41] Unclear Unclear Unclear Unclear No No Unclear High
Ma et al. [42] Unclear Unclear Unclear Unclear No No Unclear High
Hu et al. [43] Unclear Unclear Unclear Unclear No No Unclear High
Chen et al. [44] Unclear Unclear Unclear Unclear No No Unclear High
Guo et al. [45] Unclear Unclear Unclear Unclear No No Unclear High
Huang et al. [46] Unclear Unclear Unclear Unclear Yes No Unclear High
Wang et al. [47] Unclear Unclear Unclear Unclear No No Unclear High
Guo [48] Unclear Unclear Unclear Unclear No No Unclear High
Cheng [49] Unclear Unclear Unclear Unclear Yes No Unclear High
Huang et al. [50] Table of random number Unclear Unclear Unclear No No Unclear Unclear
Zhang et al. [51] Unclear Unclear Unclear Unclear Yes No Unclear High
Ye et al. [52] Unclear Unclear Unclear Unclear No No Unclear High
Shen et al. [53] Unclear Unclear Unclear Unclear No No Unclear High
Dan [54] Unclear Unclear Unclear Unclear No No Unclear High
Wu et al. [55] Unclear Unclear Unclear Unclear Yes No Unclear High
Zhang et al. [56] Unclear Unclear Unclear Unclear No No Unclear High
Yin et al. [57] Table of random number opaque envelopes Unclear Unclear Yes No Unclear Unclear
Jiang et al. [58] Unclear Unclear Unclear Unclear No No Unclear High
Wan et al. [59] Table of random number Unclear Unclear Unclear No No Unclear Unclear
Kim et al. [60] Unclear opaque envelopes Unclear Unclear Yes No Unclear Unclear
Kraft K. et al. [61] Unclear Unclear Unclear Unclear Yes No Unclear High
Macklin [62] Table of random number opaque envelopes Unclear Unclear Yes No Unclear Unclear
Flachskampf [63] Unclear opaque envelopes Unclear Unclear Yes No Unclear Unclear
Zhao and Fan. [64] Unclear Unclear Unclear Unclear Yes No Unclear High
Table 1 (continued)
Study ID Sample (M/F) Age (yrs) Diagnosis standard Intervention Control Course (day) Outcome
measure
Yin et al. [57] 41
T:4/11; C:5/10
T:49 to 56
C:51 to 57
Hypertension diagnostic
criteria (unclear)
Acupuncture Sham acupuncture
plus antihypertensive
medication
56 (30 min a day at
an easy pace during
the 8 week period)
BP; adverse
effect
Jiang et al. [58] 60
T:24/6; C:22/8
T:56.7 ± 10.3
C:57.5 ± 9.9
The National Forum
on Epidemiology of
Cardiovascular Diseases
in 1979
Acupuncture plus
western medicine
Captopril (12.5–25 mg tid) 21 (30 min a day, once
a day, for 6 days as one
therapeutic course)
BP
Wan et al. [59] 60
T:19/1; C:17/13
T:63.72 ± 8.23
C:65.24 ± 6.41
2004 The prevention and
control of hypertension
guidelines of China
Electroacupuncture Nicardipine tablets
(20 mg tid)
15 (10 min once a day,
5 days/course)
BP
Kim et al. [60] 33
T:8/4; C:8/8
T:52.08 ± 8.69
C:52.38 ± 10.3
Seventh report of the Joint
National Committee on
Prevention, Detection,
Evaluation, and Treatment of
High Blood Pressure (JNC 7)
Acupuncture Sham acupuncture 56 (20 min/time,
twice a week)
BP; adverse
effect
Kraft K. et al. [61] 14
(T/Cnot reported)
50.0 ± 4.6
(T/Cnot reported)
Hypertension diagnostic
criteria (unclear)
Acupuncture Sham acupuncture 84 (20 min/day) BP; adverse
effect
Macklin [62] 192
T1:64 T2:64 C:64
T1:56.8 ± 8.4
T2:55.9 ± 10.6
C:53.2 ± 9.5
Hypertension diagnostic
criteria (unclear)
Acupuncture Sham acupuncture 70 (twice-weekly
30 min)
BP; adverse
events
Flachskampf [63] 160
T:54/46; C:40/60
T:58.8 ± 8.2
C:58.0 ± 7.9
European Society of
Hypertension–European
Society of Cardiology
Guidelines 2003
Acupuncture Sham acupuncture
plus antihypertensive
medication
42 (each session lasted
30 min. during the ﬁrst
2 weeks, 5 sessions
were administered
weekly, and in the
following 4 weeks,
3 sessions were
administered weekly)
BP; adverse
events
Zhao and Fan. [64] 60
T:19/11; C:18/12
T:40.3 ± 11.4
C:46.1 ± 14.2
1999 WHO–ISH GMH Acupuncture Lifestyle intervention 30 (20 min/day,
10 days/course)
BP
Abbreviations: T, intervention group; C, control group.
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Fig. 2. The forest plot of outcome measure SBP.
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night rhythm variation in young patients with hypertension (systolic
blood pressure [SBP]:mean difference = −6.89 mm Hg, 95% conﬁdence
intervals = −7.25 to−6.53; diastolic blood pressure [DBP]:−1.12,
−1.94 to −0.30); Liao et al. [41] have shown that “reducing south
and reinforcing north” needling method have better effect than
oral administration captopril tablets and Aspirin in reducing blood
pressure (SBP:−6.89,−5.43 to−4.57; DBP:−3.00,−4.31 to−1.69);
Huang et al. [50] considered that acupuncture treatment has obvious
effect of decreasing blood pressure with very signiﬁcant differences
as compared with those before treatment and the control group
(SBP: −4.69, −6.64 to −2.74; DBP: −3.31, −4.58 to −2.04); Ye
et al. [52] discovered that acupuncture has obvious antihypertensive
effect, and the buck than metoprolol sustained release tablet groups
(SBP: −5.28,−6.07 to−4.49; DBP: −1.68,−2.30 to−1.06).3.3.2. Acupuncture plus western medicine versus western medicine
Ten trials [32,35,36,38–40,43,53,56,58] compared the combination
of acupuncture plus medicine compared with medicine compared. A
change in blood pressure was reported in 7 trials [38–40,43,53,56,58]
of the included RCTs. Among them, all trials demonstrated acupuncture
combined western medicine is better than western medicine alone on
SBP, and 5 trials [38,43,53,56,58] showed there are no statistically signif-
icant differences on DBP. Acupuncture plus benazepril hydrochloride
tablets [38] showed better effect compared to benazepril hydrochloride
tablets. The combinations of acupuncture and left-hand amlodipine [39]
had better effect compared to left-hand amlodipine. Acupuncture com-
binedwith captopril tablets [40,58] is superior to captopril tablets. Acu-
puncture plus amlodipine [43] is better than amlodipine used alone. The
combination of acupuncture and extended release nifedipine tablets
[53,56] surpassed extended release nifedipine tablets.
Fig. 3. The forest plot of outcome measure DBP.
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A total of three trials [60–62] reported the effect of acupuncture
individually compared with sham acupuncture. Among them, only
one trial [61] discovered the better effect on both SBP and DBP (SBP:
−2.60,−3.65 to−1.55; DBP:−2.40,−3.45 to−1.35). One trial [62]
described acupuncture is superior to sham acupuncture to reduce DBP
(−1.51,−1.81 to−1.21).
3.3.4. Acupuncture versus sham acupuncture plus western medicine
Two trials reported the effect of acupuncture compared with sham
acupuncture in combinations of western medicine. One trial [57] dis-
covered the better effect on both SBP and DBP (SBP: −7.00, −10.15
to−3.85; DBP:−4.00,−6.17 to−1.83). The other trial [63] describedthat acupuncture is superior to the combination group to reduce SBP
(−11.00,−19.62 to−2.38).
3.3.5. Acupuncture versus lifestyle intervention
Only one trial showed acupuncture individually versus lifestyle in-
tervention. There are statistically signiﬁcant differences on the acupunc-
ture group to lifestyle intervention using alone (SBP:−13.50, −15.06
to−11.94; DBP:−5.25,−6.01 to−4.49).
3.4. Adverse effect
Only six trials [54,57,60–63] described the adverse even. Among
them, two trials recorded two speciﬁc symptoms including transient
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Fig. 4. Comparison of SBP in acupuncture versus western medicine.
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in the acupuncture group. One trial reported three cases of serious ad-
verse events, in which patients stopped antihypertensive drugs during
study period [62], two participants experienced hypertensive urgencies
in the acupuncture group and one congestive heart failure in the control
group during follow-up. In addition, no adverse events were found in
three trials [54,60,61].
3.5. Publication bias
The forest plot of comparison of acupuncture versus western medi-
cine for the outcome blood pressure was shown in the Figs. 4–5.
4. Discussion
Hypertension is a major public health problemwith serious medical
and ﬁnancial consequences.Medical interventions for thosewith severe
hypertension generally have to use antihypertensive drugs such as
diuretics,α- and β-blockers, angiotensin-converting enzyme inhibitors,
and long-acting calcium-channel blockers [65]. However, barriers to
successful conventional pharmacological treatment include side effects,
out-of-pocket expenses, patient noncompliance and insufﬁcient dos-
ages of prescribed medications [66–69]. An advantage of acupuncture
is its relatively low incidence of serious or debilitating side effects [70].
Two SRs [71,72] of acupuncture on hypertension have been reported,
however, most of languages the selected databases of them are English
except 4 [60–63], much of the acupuncture literature in hypertension is
in non-English language publications. Furthermore, electronic literature
searches for RCTs to June 2007 and September 2008, they might have
left out some important studies, and new high-quality RCTs have been
recently published. Therefore, we decided to assess the current clinical
evidence of acupuncture for hypertension.
Based on the paper and meta-analyses of the outcome on either
SBP or DBP, acupuncture may have positive effects for lowing BP. Five-100 -50 0 50 100
0
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Fig. 5. Comparison of DBP in acupuncture versus western medicine.subgroupswere analyzed based onmethodological variables of acupunc-
ture arms and control arms. The BP-lowering effect of acupuncture plus
westernmedicinewas signiﬁcantly higher than that ofwesternmedicine
(SBP: −10.20, −14.00 to −6.40, P b 0.0001; DBP: −4.34, −6.79 to
−1.90, P = 0.0005). The BP also decreased signiﬁcantly from baseline
with acupuncture than sham acupuncture plus western medicine (SBP:
−7.47, −10.43 to −4.5, P b 0.00001; DBP: −4.22, −6.26 to −2.18,
P b 0.0001). Acupuncture achieved signiﬁcant effect modiﬁcation on
BP change magnitude compared with lifestyle (SBP: −13.50, −15.06
to −11.94, P b 0.00001; DBP: −5.25, −6.01 to −4.49, P b 0.00001),
whereas, comparedwithwesternmedicine, acupuncture showed no sig-
niﬁcant effect modiﬁcation (SBP: −0.77, −3.89 to −2.35, P = 0.63;
DBP: 0.10,−1.60 to 1.79, P = 0.91). Comparedwith sham acupuncture,
acupuncture statistically showed no signiﬁcant effect modiﬁcation with
statistically signiﬁcant heterogeneity (SBP: 0.26, −2.40 to 2.91, P =
0.25; DBP: −1.04, −2.56 to 0.47, P = 0.18). However, according to
potential publication bias and low-quality trials, available data are
not adequate to draw a deﬁnite conclusion of acupuncture for essen-
tial hypertension. And the positive ﬁndings should be interpreted
conservatively.
Before recommending the conclusion of this review to clinical
practice, we have to consider the following weaknesses in this
review. Firstly, in accordance with previous studies [73], the quality
of the included RCTs was generally low. The 35 trials included in this
paper had risk of bias in terms of design, reporting, methodology.
Only 8 RCTs stated randomization procedure, for the rest 27 trials,
they just mentioned that ‘the patients were randomized into two
groups’ with no further information. Allocation concealment was only
mentioned in 4 RCTs [57,60,62,63]. A number of trials [32,33,35–37,
48,49,54] only have one author, which is impossible for an RCT to be
done properly in terms of randomization procedure and the allocation
concealment. Therefore, we could suspect the truth of some of these
claimed RCTs. In addition, all the trials did not describe the blinding
in details. It directly led to performance bias and detection bias due to
patients and researchers being aware of the therapeutic interven-
tions for the subjective outcome measures. If poorly designed, all
the trials would show larger differences compared with well designed
trials [74,75].
Secondly, heterogeneity is worthy of being paid attention to. Many
factors affect the effects of heterogeneity, such as acupuncture modali-
ties, acupoint selection, frequency and duration of the treatment
sessions. One of the major limitations was the application of various
kinds of acupuncture point treatments used in different trials. More
than 30 different acupoints were investigated in the 35 trials. The
acupoints differed in meridians, syndromes, and the clinical efﬁcacy. It
is difﬁcult to assess the effect of a particular acupuncture point by
means of the evidence synthesis of studies. As a result, it is impossible
to conductmeaningfulmeta-analysis for a speciﬁc acupoints, or difﬁcult
to undertake subgroup analyses to explore speciﬁc factors that may
have an impact on the effects of the treatment regimen. In addition,
two acupuncture modalities were reported, i.e. manual acupuncture
and electroacupuncture. Most of them used manual acupuncture and
electroacupuncture was selected in 4 RCTs [37,38,42,59]. In addition,
the differences of frequency and duration of the treatment sessions
(10 to 30 min per session acupuncture treatments, ranged from 10 to
90 days) affected the effects of acupuncture, thus made contributions
to the great heterogeneity. Not only that, all trials speciﬁed 10 diagnos-
tic criteria of hypertension without 7, selective reporting bias might
exist in this conclusion, and reduce the homogeneity of the research
objects. All the 24 RCTs prohibited us to performmeaningful sensitivity
analysis.
Thirdly, only 6 trials of 24 trials did mention adverse effect. Even for
the trials that reported adverse events, their report was very brief, pro-
viding limited information. Therefore, a conclusion about the safety of
acupuncture cannot be made clearly. Five trails reported information
on follow-up, but not mentioned the details. In order to properly assess
325J. Wang et al. / International Journal of Cardiology 169 (2013) 317–326the safety of acupuncture, large-scale clinical trials with long-term
follow-up are required.
In addition, of the 35 included trials, most of them were in Chinese
language and only 3 in English language, and one in German language.
China generates virtually no ‘negative’ studies at all. In other word, pub-
lication and other biases may play an important role. We tried to take
all measures to contact authors to get further information either by tele-
phone, letter, or e-mail. Unfortunately, we got no replies, andwe are not
sure, the trials were conducted as true RCT.
In summary, our study showed that acupuncture could lower SBP
and DBP, however, because of the unclear methodological quality of
these identiﬁed trials, a deﬁnite conclusion on efﬁcacy and adverse
events associated with acupuncture cannot be drawn from this review.
Therefore, further thorough investigation, large-scale, rational study de-
sign, randomized trials of acupuncture for hypertensionwill be required
to justify the effects reported here. Future trials should overcome the
limitations of the trials presented in this review; particularly, they
should assure adequate concealment of allocation and blinding of out-
come assessors and use functional outcome as the primary outcome
measured at long-term follow-up. Reports of the trials should conform
to the recommendations of the CONSORT statement [76]. If reliable
RCT results conﬁrmed acupuncture positive effects for treatment of
hypertension, it would be blessing news to use complementary and
alternative medicine for hypertension.
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